Brought to you by 
bioMerieux, Pierre Fabre merge; then part ways
24 Jan 2003
Executive Summary
BioMerieux (in vitro diagnostics focusing on infectious diseases) and Pierre Fabre (pharmaceuticals for immunology, CNS, and the cardiovascular system; and dermo-cosmetics) merged to form bioMerieux-Pierre Fabre. The new enterprise will be equally owned by both of the originating companies.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
bioMerieux, Pierre Fabre merge; then part ways
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice